Clinical trial
A Randomized Study of Sulindac in Oral Premalignant Lesions
NCT00299195 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00299195 |
|---|---|
| Title | A Randomized Study of Sulindac in Oral Premalignant Lesions |
| Official title | A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | AIMS Institute Weill Medical College of Cornell University Regional Cancer Centre, Trivandrum, India Narayana Hrudayalaya Hospitals |
| Status | Completed |
| Study type | Interventional |
| Conditions | Leukoplakia, Oral, Benign Neoplasms |
| Intervention type | Drug |
| Interventions | sulindac, Placebo |
| Enrollment | 63 |
| Start date | Feb 23, 2006 |
| Primary completion | Jan 6, 2020 |
| Completion | Jan 6, 2020 |
| First posted | Mar 6, 2006 |
| Last update posted | Nov 19, 2020 |
| Countries | India, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: